JAMA Oncology

09/10/2026

Among patients with persistent, recurrent, or metastatic , pembrolizumab plus platinum-based chemotherapy with or without bevacizumab maintained overall survival and progression-free survival benefit at 5 years vs chemotherapy alone. Long-term safety remained consistent, with no new safety signals observed, supporting this regimen as a first-line standard-of-care option.

This exploratory analysis of the KEYNOTE-826 randomized clinical trial evaluates clinically relevant 5-year follow-up results.

09/08/2026

A 76-year-old man presented to the emergency department with 5 days of worsening dyspnea at rest, lower extremity edema, fatigue, confusion, and poor oral intake. What is your diagnosis?

A 76-year-old man presented to the emergency department with 5 days of worsening dyspnea at rest, lower extremity edema, fatigue, confusion, and poor oral intake. What is your diagnosis?

09/08/2026

Among children with relapsed or refractory , bicistronic therapy targeting CD19 and CD22 was associated with high rates of minimal residual disease–negative remission. Event-free survival remained durable through follow-up, and outcomes were more favorable among patients who received consolidative transplant.

This nonrandomized clinical trial examines the safety and efficacy of bicistronic CD19/CD22 chimeric antigen receptor T-cell therapy in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

09/07/2026

Among patients with -positive , neoadjuvant anbenitamab plus HB1801 was associated with a higher total pathologic complete response rate vs trastuzumab, pertuzumab, and docetaxel, with or without carboplatin.

Grade 3 or 4 treatment-related adverse events were similar between groups, indicating improved response without an increase in severe toxic effects.

https://ja.ma/46L3ZYY

09/07/2026

💬 Editorial: In pediatric , bicistronic CD19/CD22 therapy was associated with durable remission despite limited persistence, challenging the view that prolonged CAR T-cell surveillance is always required.

In this issue of JAMA Oncology, Wan et al1 report a cohort of 261 pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with bicistronic anti-CD19/CD22 chimeric antigen receptor (CAR) T-cell therapy. This nonrandomized clinical trial achieved remarkable...

09/07/2026

📝 JAMA Oncology Patient Page: Supplements and Wellness Products During Care Many people with cancer may consider supplements or wellness products during treatment. Some hope to improve energy, support the immune system, reduce treatment side effects, or feel more in control during a difficult time. These products may include herbal supplements, detox cleanses, high-dose vitamin infusions, or products marketed online as immune support or natural wellness products. This Patient Page discusses safety when taking supplements and wellness products during cancer treatment.

This JAMA Oncology Patient Page discusses safety when taking supplements and wellness products during cancer treatment.

09/07/2026

📑 JAMA Oncology Review: The treatment of older adults with for early-stage involves a complex decision-making process that weighs the competing risks of disease recurrence against the potential harms of treatment. While older adults continue to be underrepresented in therapeutic clinical trials, there is a growing body of evidence to support optimal management of each subtype of early-stage breast cancer, including novel strategies like adjuvant cyclin-dependent kinase 4/6 inhibitors in hormone receptor–positive disease, and the neoadjuvant use of pembrolizumab in triple-negative breast cancer. This review will help clinicians best use the available data and decision-making tools to support best practice for treating older adults with early-stage breast cancer and will highlight ongoing clinical trials aimed at optimizing medical care for this patient population.

This narrative review discusses chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage breast cancer.

09/06/2026

After biosimilar entry for biologics including bevacizumab, rituximab, and trastuzumab, reference product prices and market share declined in commercial insurance and Medicare Part B.

Patients who exclusively used had lower mean monthly payer costs and lower mean monthly out-of-pocket costs vs those who exclusively used reference biologics, indicating reduced financial burden for payers and patients.

https://ja.ma/4xQXeAT

09/06/2026

mortality in the US declined from 2000 to 2019 among adults aged ≥45 years across racial and ethnic groups and by s*x, but county-level disparities remained substantial.

In 2019, some counties still had rates >100 deaths per 100 000, with the highest burdens concentrated among American Indian or Alaska Native and Black populations, indicating a need for more targeted local public health and screening strategies.

https://ja.ma/4zTjfjT

09/06/2026

In a comparative study of US clinical trial portfolios, federally sponsored trials were less likely than industry-sponsored trials to focus on single-agent drug therapies for treatment.

Federal sponsors were more likely to evaluate nontreatment interventions, including prevention and supportive care, indicating complementary roles in the cancer research enterprise.

https://ja.ma/4cylzD3